Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Conor O'Shea

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Circulation. Cardiovascular Interventions|December 25, 2009
Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trialJames E Tcheng, Ing Haan Lim, Shankar Srinivasan, et al.
Journal of the American College of Cardiology|February 11, 2003
Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trialThaddeus R Tolleson, J Conor O'Shea, John A Bittl, et al.
The American Journal of Cardiology|December 31, 2002
Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial)Donal N Reddan, John Conor O'Shea, Ian J Sarembock, et al.
Journal of the American College of Cardiology|January 8, 2011
Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysisRajendra H Mehta, J Conor O'Shea, Amanda L Stebbins, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|January 5, 2007
Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trialJean-Pierre Dery, Mark E Campbell, Jasmine Mathias, et al.
The Journal of Invasive Cardiology|July 9, 2005
Bailout use of platelet glycoprotein IIb-IIIa inhibition during coronary stent implantation: observations from the ESPRIT trialWarren J Cantor, Mina Madan, J Conor O'Shea, et al.
ACS Omega|July 25, 2022
Using NMR to Dissect the Chemical Space and <i>O</i>-Sulfation Effects within the <i>O</i>- and <i>S</i>-Glycoside Analogues of Heparan SulfateMaria C Z Meneghetti, Lucy Naughton, Conor O'Shea, et al.
Journal of Interventional Cardiology|May 29, 2003
Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary interventionJames E Tcheng, Mina Madan, J Conor O'Shea, et al.
Journal of the American College of Cardiology|October 2, 2002
Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT studyLaura S Fernandes, James E Tcheng, J Conor O'Shea, et al.
The Journal of Invasive Cardiology|September 9, 2004
Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experienceWarren J Cantor, James E Tcheng, James C Blankenship, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Circulation. Cardiovascular Interventions|December 25, 2009
Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trialJames E Tcheng, Ing Haan Lim, Shankar Srinivasan, et al.
Journal of the American College of Cardiology|February 11, 2003
Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trialThaddeus R Tolleson, J Conor O'Shea, John A Bittl, et al.
The American Journal of Cardiology|December 31, 2002
Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial)Donal N Reddan, John Conor O'Shea, Ian J Sarembock, et al.
Journal of the American College of Cardiology|January 8, 2011
Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysisRajendra H Mehta, J Conor O'Shea, Amanda L Stebbins, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|January 5, 2007
Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trialJean-Pierre Dery, Mark E Campbell, Jasmine Mathias, et al.
The Journal of Invasive Cardiology|July 9, 2005
Bailout use of platelet glycoprotein IIb-IIIa inhibition during coronary stent implantation: observations from the ESPRIT trialWarren J Cantor, Mina Madan, J Conor O'Shea, et al.
ACS Omega|July 25, 2022
Using NMR to Dissect the Chemical Space and <i>O</i>-Sulfation Effects within the <i>O</i>- and <i>S</i>-Glycoside Analogues of Heparan SulfateMaria C Z Meneghetti, Lucy Naughton, Conor O'Shea, et al.
Journal of Interventional Cardiology|May 29, 2003
Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary interventionJames E Tcheng, Mina Madan, J Conor O'Shea, et al.
Journal of the American College of Cardiology|October 2, 2002
Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT studyLaura S Fernandes, James E Tcheng, J Conor O'Shea, et al.
The Journal of Invasive Cardiology|September 9, 2004
Temporal spectrum of ischemic complications with percutaneous coronary intervention: the ESPRIT experienceWarren J Cantor, James E Tcheng, James C Blankenship, et al.
Pageof 4